top of page
Asian Institute of Research, Journal Publication, Journal Academics, Education Journal, Asian Institute
Asian Institute of Research, Journal Publication, Journal Academics, Education Journal, Asian Institute

Journal of Health and Medical Sciences

ISSN 2622-7258

Screen Shot 2018-08-12 at 1.24.09 AM.png
Screen Shot 2018-08-12 at 1.24.02 AM.png
Screen Shot 2018-08-12 at 1.23.57 AM.png
Screen Shot 2018-08-12 at 1.23.52 AM.png
open access

Published: 10 May 2022

DNA Cell Cycle Analysis with Propidium Iodide (PI) in Liver Cancer Patients

Mohamed Hussein

Dubai Medial College, United Arab Emirates

journal of social and political sciences
pdf download

Download Full-Text Pdf



Pages: 74-80

Keywords: Hepatocellular Carcinoma, HCV, NASH


Hepatocellular Carcinoma (HCC) ranks as the fifth most common cancer and, with over 600,000 deaths per annum, it constitutes a major global health problem. The main aetiologies of chronic liver injury are chronic hepatitis C virus (HCV) and hepatitis B virus (HBV) infections, alcohol abuse and, as a result of metabolic syndrome reaching epidemic proportions, an increasing prevalence of non-alcoholic steatohepatitis (NASH). Biomarkers are being developed as alternatives to liver biopsy for predicting liver fibrosis in patients with chronic hepatitis C. The aim of this study was to investigate DNA Cell cycle in HCC, Fibrosis patients and compare with healthy control group. They were classified into three different groups 51 individuals diagnosed Fibrosis patients, 30 Hepatocellular Carcinoma patients and 40 healthy Control individuals with no liver diseases. Tumor Markers including CEA and AFP were estimated using ELISA method, DNA cell cycle was assessed using Flow Cytometry. Results showing sub G1 was increased significantly in both HCC and Fibrosis patients with values 9.55 ± 4.72 and 17.7 ± 5.9; respectively comparing with Healthy control group 5.7 ± 3.36 (p<0.005). On the other hand, G0/G1 was decreased significantly in both HCC and Fibrosis patients with values 62.2 ± 10.02 and 53.4 ± 11.1, respectively while in Healthy control. In addition, AFP and CEA were increased in both HCC and Fibrosis patients comparing with Control. Conclusion based on this study DNA cell cycle could help in assessment of Liver damage especially HCC.


  1. Dufour D.R., Lott J.A., Nolte F.S., Gretch D.R., Koff R.S., and Seeff L.B., (2000): Diagnosis and monitoring of hepatic injury II Performance characteristics of laboratorytests. J. Clin.Chem., 46: 2050-68.

  2. Akiba J., Umemura T., Alter H.J., Kojiro M., and Tabor E., (2005): SEN virus: epidemiology and characteristics of a transfusion-transmitted virus. Transfusion, 45: 1084-88.

  3. Herzer K., Sprinzl M.F., and Galle P.R., (2007): Hepatitis viruses: Live and let die. Liver Int., 27: 293-301.

  4. Michielsen P.P., Francque S.M., and Van Dongen J.L., (2005): Viral hepatitis and hepatocellular carcinoma. Word J. surg. Oncol. 3: 27.

  5. Michalopoulos G.K., (2010): Liver regeneration after partial hepatectomy: Critical analysis of mechanistic dilemmas. Am. J. Pathol, 176, 2–13.

  6. Hashimoto E., Taniai M., Kaneda H., Tokushige K., Hasegawa K., Okuda H., Shiratori K., and Takasaki K., (2004): Comparison of hepatocellular carcinoma patients with alcoholic liver disease and nonalcoholic steatohepatitis. Alcohol Clin. Exp. Res.; 28: 164S- 168S.

  7. Johnson D.G., Walker C.L., (1999): Cyclins and cell cycle checkpoints. Annu Rev Pharmacol Toxicol. 39: 295-312.

  8. Sumpter R , Loo Y-M , Foy E , et al . Regulating intracellular antiviral defense and permissiveness to hepatitis C virus RNA replication through a cellular RNA helicase, RIG-I. J Virol 2005;79:2689–99

  9. Wai C.T., Greenson J.K., Fontana R.J., Kalbfleisch J.D., Marrero J.A., Conjeevaram H.S., Lok A.S., (2003): A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology; 38: 518–526.

  10. Sterling R.K., Lissen E., Clumeck N., Sola R., Cassia Correa M., Montaner J., Sulkowski M., Torriani F.J., Dieterich D.T., Thomas D.L., Messinger D., Nelson M., (2006): Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology; 43: 1317–1325.

  11. Silver K., Gold P., Feder S., Freedman O., Shuster J., (1973): Radioimmunoassay for Human Alpha-1 Fetoprotein. Proc Natl Acad Sci USA; 70(2):526–30.

  12. Hansen, J., LaFontaine, G., Newman S., Schwartz, K., Malkin, A., Mojzisik, K., Martin E.W., Goldenberg D.M., (1989): Solving the problem of antibody interference in commercial ‘‘sandwich’’-type immunoassays of carcinoembryonic antigen. Clin Chem; 35:146–51.

  13. Vindelov, L., et al., Cytometry, 3, 317 (1983).

  14. El-Zanaty F., Way A., (2009): Egypt Demographic and Health Survey 2008. Cairo, Egypt: Ministry of Health, El-Zanaty and Associates, and Macro International

  15. Pileri P., Uematsu Y., Campagnoli S., Galli G., Falugi F., Petracca R., Weiner A.J., Houghton M., Rosa D., Grandi G., Abrignani S., (1998): Binding of hepatitis C virus to CD81. Science; 282: 938-941.

  16. Zhang J., Randall G., Higginbottom A., Monk P., Rice C.M., McKeating J.A., (2004): CD81 is required for hepatitis C virus glycoprotein-mediated viral infection. J Virol; 78: 1448-1455.

  17. Domingo E.O., Lingao A.L., Lao J.Y., (2013): The significance of common laboratory tests in hepatocellular carcinoma. Philippi J Inter Med; 51:1–3.

  18. Massoud A., Reda M., Shaker M., (2006): Detection of hepatitis B and C viruses in hepatocellular carcinoma tissue. In Liver International, 24th Biennial Meeting of the International Association for the study of the Liver (IASL) in collaboration with the African Association for the Study of Liver Diseases (AFASLD); 26:67–77.

  19. Lok A.S., Everhart J.E., Wright E.C., Di Bisceglie A.M., Kim H.Y., Sterling R.K., Everson G.T., Lindsay K.L., Lee W.M., Bonkovsky H.L., Dienstag J.L., Ghany M.G., Morishima C., Morgan T.R., (2011): Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. Gastroenterology; 140: 840- 849; quiz e12.

  20. Tangkijvanich P, Anukulkamkusol N, Suwangool P, Lert-maharit S, Hanvivatvong O, Kullavanijaya P, et al. Clinical characteristics and prognosis of hepatocellular carcinoma: analysis based on serum alpha-fetoprotein levels. J Clin Gastroenterol. 2000;31:302–8.

  21. Martínez-Alonso and Liu, L., Michowski, W., Kolodziejczyk, A., and Sicinski, P. (2019). The Cell Cycle in Stem Cell Proliferation, Pluripotency and Differentiation. Nat. Cel Biol 21 (9), 1060–1067. doi:10.1038/s41556-019-0384-4

  22. Martínez-Alonso, D., and Malumbres, M. (2020). Mammalian Cell Cycle Cyclins. Semin. Cel. Dev. Biol., 107, 28–35. doi:10.1016/j.semcdb.2020.03.009

bottom of page